The Food and Drug Administration on Monday proposed a regulation that would allow N-acetyl-L-cysteine, the compound sold for more than 30 years as the supplement NAC, to be marketed lawfully as a dietary supplement. If finalized, the proposed rule would lift the exclusion that has kept NAC outside the legal definition of a supplement because it was approved as a drug first.

The document went on public inspection Monday morning and is scheduled for formal publication in the Federal Register on Tuesday. It would create a new section of federal regulations for ingredients that are not excluded from the supplement definition even though they otherwise would be, with NAC as the first and so far only entry and a second slot held in reserve. In its announcement of the proposal, the FDA said the step is the first time it has used the rulemaking authority written into the exclusion clause of the supplement definition.

Health and Human Services Secretary Robert F. Kennedy Jr. signed the proposal. Under it, products containing NAC could be sold as supplements so long as they do not otherwise violate the Federal Food, Drug, and Cosmetic Act, and adding NAC to a supplement would no longer be a prohibited act. Those products would still have to meet existing supplement rules, including manufacturing standards, and adulterated or misbranded products could still draw enforcement, Nutritional Outlook reported. The agency proposed that a final rule take effect the day it is published rather than after the usual 30 days, on the ground that it would relieve a restriction.

NAC's legal trouble comes down to timing. The FDA approved acetylcysteine as a new drug on Sept. 14, 1963, under the brand name Mucomyst, and says it knows of no evidence the compound was sold as a food or supplement before then. The earliest supplement marketing the agency cites is a 1991 advertisement. When Congress defined dietary supplements in 1994, it excluded any article approved as a drug before it was marketed as a supplement or food, unless the government issues a regulation, after public notice and comment, finding the article lawful. That regulation is what the FDA has now proposed.

The agency has restated the exclusion repeatedly over the past 25 years: in a 2001 response to a health claim petition, in 2010, and in July 2020 warning letters to companies marketing supplements as hangover remedies. Two citizen petitions filed in 2021, which Nutritional Outlook identified as coming from the Council for Responsible Nutrition and the Natural Products Association, asked the FDA to change course. In March 2022 the agency denied one outright and the other in part, while saying it was considering rulemaking. That August it issued guidance promising temporary enforcement discretion for NAC products labeled as supplements. The FDA said it will keep that policy in place while the rule moves forward and intends to withdraw the guidance once a final rule is issued.

The proposal leans on a safety review the FDA conducted to inform the rulemaking. The agency's systematic review of published studies of NAC taken by mouth identified 41 it rated high confidence, with doses as high as 9,000 milligrams a day and treatment lasting up to three years. One study found a significant increase in nausea among patients given NAC; most of the others reported no adverse events or none that differed significantly from comparison groups. The agency rated the level of concern as minimal and said the review's protocol, analysis and conclusions were externally peer reviewed. Common supplement servings of 600 to 1,200 milligrams a day fall within the doses studied, Nutritional Outlook reported. In its announcement, the FDA said the review found no safety concerns, and it noted that NAC supplements have been sold in the United States for more than 30 years and that consumers continue to seek them out.

The exclusion clause exists for reasons the proposal itself lays out. Congress included it, the FDA wrote, to keep manufacturers from escaping drug safety and effectiveness review by labeling products as supplements, and to protect the incentive to develop new drugs. On the second point, the agency noted that acetylcysteine remains an approved drug, counted at least 19 current generic applications for it and 832 clinical trials studying it as a drug, and observed that the work continued while supplement versions were on sale. It said it has no reason to believe the change would affect current or future NAC drug development, but it asked the public to weigh in on that question.

STAT, which called the proposal a win for supplement advocates including members of the Make America Healthy Again movement, noted that the unusual classification is needed because the FDA had approved NAC as a drug, and that the compound is already widely sold over the counter.

The economic stakes in the agency's own analysis are small. It estimates annualized costs of roughly $99 to $121, mostly for companies to read and understand the rule, and did not attempt to estimate benefits, though it said consumers could gain if firms bring new products to market once the legal question is settled. The FDA's announcement said the proposal, if finalized, would count as a deregulatory action under President Trump's Executive Order 14192, Unleashing Prosperity Through Deregulation.

Comments will be accepted for 60 days after publication under docket FDA-2025-N-2699. The agency is asking for any evidence that NAC was sold as a food or supplement before its 1963 drug approval, along with views on the drug development question and the proposed immediate effective date. Until a final rule is issued, NAC supplements that otherwise comply with the law remain covered by the 2022 enforcement discretion policy rather than by a formal legal finding.